European Archives - Page 494 of 1103 - European Medical Journal

Dermatology CP

Paget Disease of Skin Secondary to Urothelial Carcinoma

Currently, the exact mechanism underlying EMPD is unknown, but two widely known theories exist, namely the epidermotropic and transformation theories.

EMJ Hematology 10 [Supplement 2] 2022

EXPERT discussion from a satellite symposium presented at the European Hematology Association (EHA) Virtual Congress 2021 focused on myelodysplastic syndrome (MDS), a heterogeneous group of myeloid malignancies characterised by ineffective haematopoiesis, progressive bone marrow failure, and increased risk of acute myeloid leukaemia evolution.

Idarucizumab in Emergent Pericardiocentesis

A 71-year-old male with atrial fibrillation (AF) was admitted to the authors’ emergency department with fever, progressive dyspnoea…

Treatment with Hyaluronic Acid Injections in a Patient with Craniosynostosis

A case of a 25-year-old White female left with residual bone deformity after surgical correction of craniosynostosis during childhood…

EMJ

The Search for Sustained Durability in Higher-Risk Myelodysplastic Syndrome: New Treatment Pathways in Sight

Higher-risk MDS is a collective term based on the Revised International Prognostic Scoring System (IPSS-R) that encompasses…

New Developments, Data, and Guideline Updates: Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism Associated with Cancer – Interviews with Key Opinion Leaders

CAT is a serious complication that can affect up to 6% of patients with cancer, and is associated with a 2–5-fold increased risk of…

EMJ Oncology 10 [Supplement 3] 2022

In this interview, they discuss the role of direct oral anticoagulants (DOAC) as a treatment for cancer-associated thrombosis (CAT)…

Levelling the Playing Field

In this episode, Jonathan is joined by Dr Steve Wexner, Chairman of the Department of Colorectal Surgery at the Cleveland Clinic, Miami, Florida, USA.

The return of the vaccines

The pandemic revived all areas of vaccine development. Read more about the effect of Covid-19 on investment, development and commercialisation of vaccines.

R&D progress on the rise

Pharmaceutical R&D saw sustained growth in clinical trial activity and a record number of novel active substances launched in 2021, according to a new report from IQVIA.